Highpoint Advisor Group buys $6,864,093 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Highpoint Advisor Group scooped up 28,786 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 55,706 shares of Johnson & Johnson which is valued at $6,864,093.Johnson & Johnson makes up approximately 2.42% of Highpoint Advisor Group’s portfolio.

Other Hedge Funds, Including , Zwj Investment Counsel Inc reduced its stake in JNJ by selling 1,075 shares or 0.67% in the most recent quarter. The Hedge Fund company now holds 158,838 shares of JNJ which is valued at $19,659,379. Johnson & Johnson makes up approx 1.97% of Zwj Investment Counsel Inc’s portfolio.Fernwood Investment Management reduced its stake in JNJ by selling 240 shares or 1.24% in the most recent quarter. The Hedge Fund company now holds 19,167 shares of JNJ which is valued at $2,381,308. Johnson & Johnson makes up approx 2.23% of Fernwood Investment Management’s portfolio.

Johnson & Johnson (JNJ) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $119.91 and reached the intraday high at $119.99. The bulls started the profit booking and pushed the shares to intraday low of $119.32. The trading session was marked by a volume range of 77,98,299 shares exchanging hands. The 52-week high of the shares is $126.07 and the 52-week low is $81.79. The market cap of the company stands at $328,086 M and there are 2,73,58,76,800 shares in public circulation.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.